Frontline therapy in multiple myeloma: fast start for a long game
نویسندگان
چکیده
منابع مشابه
Review Series MULTIPLE MYELOMA: FROM THE BENCH TO BEDSIDE Frontline therapy of multiple myeloma
Multiple myeloma (MM) accounts for 1% of all cancers and ;13% of all hematologic malignancies. Approximately 86 000 new cases of MM occur annually worldwide. This malignant neoplasm primarily affects elderly individuals with a median age at the time of diagnosis of ;70 years. Active MM is consistently preceded by precursor states of monoclonal gammopathy of undetermined significance and smolder...
متن کاملPosttransplantation maintenance therapy and optimal frontline therapy in myeloma.
One of the major efforts to improve the results of intensive therapy and autologous stem cell transplantation (ASCT) in multiple myeloma involves the integration of novel agents into the transplantation sequence. This can include their administration before, during, and after the transplantation procedure. Several phase 2 and 3 studies have evaluated the use of novel agents as part of induction...
متن کاملLenalidomide: a new therapy for multiple myeloma.
The last decade has seen rapid evolution in the management of multiple myeloma. Cytogenetic, molecular, and proteomic techniques have led to a better understanding of the pathophysiology and prognostic markers of this heterogeneous malignancy. New immunomodulatory drugs, such as lenalidomide, which interrupt myeloma growth and survival pathways have entered into clinical usage. Combined with de...
متن کاملMultiple Myeloma Update
This literature review presents the most recent developments in the management of multiple myeloma, which is characterized by the presence of abnormal plasma cells (myeloma cells) that accumulate into the bone marrow. Aspects related to pathophysiology, clinical manifestations, laboratory, study and treatment are described. These pieces of information are necessary to accomplish a better ...
متن کاملTargeted therapy in multiple myeloma.
BACKGROUND Multiple myeloma (MM) is an incurable malignancy. Recent insights into its biology has allowed the use of novel therapies targeting not only the deregulated intracellular signaling in MM cells but also its interaction with the bone marrow microenvironment that confers drug resistance, growth, and survival advantage to the malignant cells. METHODS We review and summarize the recent ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Haematology
سال: 2019
ISSN: 2352-3026
DOI: 10.1016/s2352-3026(19)30199-1